Nexiguran ziclumeran

N/A

Report date: 2026/04/17 20:02:02

Base Information

Drug NameNexiguran ziclumeran
Drug Alias Namenex-zNTLA-2001
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9
Mechanisms of ActionTransthyretin inhibitorsGene modulators
TargetsTransthyretin
Therapy Area/IndicationsTransthyretin amyloidosisAmyloidosisMetabolic Diseases +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[27] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesIntellia Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesIntellia Therapeutics IncRegeneron Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsTransthyretin amyloidosisAmyloidosisMetabolic Diseases +[14] 
Inactive IndicationsNervous System Diseases

Other Information

ATC CodeN/A
Related LinksN/A